Journal Article

Pancreatitis Treated with Didanosine and Tenofovir Disoproxil Fumarate

Jennifer N. Blanchard, Michael Wohlfeiler, Albert Canas, Kevin King and J. Tyler Lonergan

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 5, pages e57-e62
Published in print September 2003 | ISSN: 1058-4838
Published online September 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/376991
Pancreatitis Treated with Didanosine and Tenofovir Disoproxil Fumarate

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. Tenofovir disoproxil fumarate increases the plasma levels of didanosine and, thus, the combination of these agents may increase the risk of pancreatitis. Four cases of pancreatitis that occurred during administration of this drug combination are examined, including 1 that resulted in death.

Journal Article.  3737 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.